Moderna seeks US authorisation for vaccine in children under six
Al JazeeraTrial included 4,200 children aged two to six years and 2,500 babies aged six months to two years. US biotech firm Moderna said on Thursday it had submitted a request for an emergency use authorisation in the United States for its COVID-19 vaccine for children aged six months to under six years. Vaccine efficacy in children six months up to age two was 51 percent, and efficacy was 37 percent in the two to five years age group, when limiting the analysis to only cases confirmed positive on a positive PCR test. Pfizer’s vaccine, when given as two doses of three micrograms to children aged six months to two years elicited a similar level of antibodies to the full 30 micrograms given to people aged 16-25, but the same was not true for children between two and four.